Smith & Nephew plc (LON:SN, NYSE:SNN), the global medical technology business, announced its trading report for the third quarter ended 29 September 2018.
Namal Nawana, Chief Executive Officer of Smith & Nephew, said:
“Improved underlying revenue growth in the third quarter was led by growth in the US and Emerging Markets. We are on-track to deliver our full year guidance.
“These results were achieved whilst successfully redesigning how we will run the company. There is still more to do, and I am pleased with the pace of progress and engagement across the organisation.”
Q3 Highlights1,2
· Q3 revenue $1,169 million, up 2% on a reported and 3% on an underlying basis
· Underlying revenue growth of 4% in the US, and 10% in the Emerging Markets
· Strong growth in Reconstruction, Sports Medicine Joint Repair and Advanced Wound Devices
· Advanced Wound Bioactives continued to decline
· Full year guidance reconfirmed
· Moving to new global commercial structure to unlock value through specialist global franchises
